Calithera Biosciences Inc

NASDAQ:CALA   10:38:38 AM EDT
2.72
+0.12 (+4.62%)
Products, Regulatory

Calithera Biosciences Announces First Patient Enrolled In Phase 2 Clinical Trial Of Mivavotinib In Relapsed/Refractory Non-Gcb (Abc) Diffuse Large B-Cell Lymphoma

Published: 06/23/2022 21:02 GMT
Calithera Biosciences Inc (CALA) - Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/refractory Non-gcb (abc) Diffuse Large B-cell Lymphoma.
Calithera - Study Will Evaluate Syk Inhibitor Both in Patients With Wild-type Disease and Those With Tumors That Harbor Myd88 Or Cd79b Mutations.
Calithera - Data From Trial Could Position Co to Initiate a Study With Registrational Intent in Biomarker-specific Dlbcl Populations.